JUNS
JUPITER NEUROSCIENCES, INC.
NASDAQ · Healthcare · Biotechnology · US
$2.86
−4.98%Price chart
Aug 19Aug 24Aug 27Sep 1Sep 4Sep 10Sep 15Sep 18
Key dataSep 18, 2026
Open$3.05
From 52W high−63.19%
Volume17621.00
Market cap$3.77M
P/E (TTM)—
P/S (TTM)58.3x
Div yield—
Key dataSep 18, 2026
Open
$3.05
From 52W high
−63.19%
Volume
17621.00
Market cap
$3.77M
ValuationView details →
P/E (Fwd)
1.9x
EV/EBITDA
−0.4x
P/E (TTM)
—
RSI (14)
44.0
MomentumView details →
1D Return
−4.98%
YTD Return
+199.02%
SummaryUpdated Jun 1, 2026
Jupiter Neurosciences, Inc. (OTC:JUNS) is a clinical-stage biotechnology company founded in 2016 and headquartered in Jupiter, Florida. Originally established as Jupiter Orphan Therapeutics, Inc., the company rebranded to its current name in August 2021 to better reflect its focus on neurological conditions. Jupiter Neurosciences went public in January 2022 and specializes in developing treatments for rare neurological diseases and neurodegenerative conditions using a resveratrol-based platform technology.
Similar companies
Latest newsMore news →
Jupiter Neurosciences, Inc. forgave accrued and unpaid compensation owed to its executives Christer Rosén, Alison Silva, Marshall Hayward, and Alexander Rosén, effective August 26, 2026.25d agoJupiter Neurosciences, Inc. appointed Alison Silva as Chief Operating Officer and President, effective June 5, 2026, with an option grant to purchase up to 600,000 shares of common stock under the 2025 Equity Incentive Plan vesting over three years from September 2, 2026.108d ago